DHM regulates the translocating ability of β-catenin through the ERK1/2 pathway, thereby affecting the performance of the target S100A4 and ultimately inhibiting the migration ability of cervical cancer cells. This evidence concerns the gene MAPK3 and cervical carcinoma.